Canada Bans Ipca Imports Based On U.S. FDA Citations
This article was originally published in PharmAsia News
Executive Summary
Canada has joined the U.S. in blocking imports of active pharmaceutical ingredients from an Indian plant of Ipca Laboratories.
You may also be interested in...
Ipca On Tailspin After Three-Plant FDA Ban
Ipca Laboratories was pummeled on Indian bourses after the US FDA barred all but one product from three of its facilities that have been grappling with compliance-related issues, piling up more pressure on the firm.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.